Clinical Trial Update: SNX-5422 to Treat Solid Tumor Cancers and Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial results for SNX-5422 in solid tumors and lymphomas have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• SNX-5422

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Neoplasms | Phase 1 | Status: COMPLETED